Prescription Drug Price Transparency
Related Sites
Prescription Drug Price Transparency Information for Reporting Entities
In January 2022, prescription drug manufacturers began reporting to the Minnesota Department of Health (MDH) on new-to-market drugs and drugs with certain levels of price growth under the Prescription Drug Price Transparency Act (MS 62J.84, subdivisions 3 and 4).
In addition to this requirement for manufacturer reporting, beginning in January 2024, all prescription drug manufacturers, pharmacies, wholesalers and pharmacy benefit managers will be required to report on drugs of substantial public interest named by MDH (MS 62J.84, subdivisions 10-14).
Please refer to this page to monitor progress, access resources, ask questions and sign up for our email updates for news and notifications.
Register and Submit a Report
Manufacturers, wholesalers, pharmacies, pharmacy benefit managers, and third-party associates submitting a report under the Minnesota Prescription Drug Price Transparency Act (MS 62J.84) may access the online system at Rx Data Portal. Go to the Rx Data Reporting Portal Help page for specific instructions on registration and report submission.
- Ongoing: registration requirement in effect.
- On August 1, 2024, MDH issued notification to reporting entities informing them that they are required to submit data under the first list of Drugs of Substantial Public Interest; detail about the requirement and lists are available below in Reporting Resources.
- Reporting entities now have 60 days, or until September 30, 2024, to submit the required data.
- MDH expects to release the second List of Drugs of Substantial Public Interest in the fall of 2024.
The Minnesota Department of Health (MDH) created several resources to support reporting entities in understanding the Prescription Drug Price Transparency Act and how to comply:
- RxPT Form and Manner Document—August 2024 (PDF)—minor corrections to June 2024 version
- Public Interest Lists
- NEW-Frequently Asked Questions for RxPT Reporting Entities: Public Interest Reporting Supplemental Questions—September 2024 (PDF)
- Frequently Asked Questions for RxPT Reporting Entities: Public Interest Reporting—June 2024 (PDF)
- Frequently Asked Questions for RxPT Reporting Entities: Price Growth and New Drug Reporting—September 2022 (PDF)
For instructional videos and user guides for the online reporting system at Rx Data Portal, please view MDH's Rx Data Reporting Help page.
Manufacturers
What drug price reporting obligations do Manufactures have in MN?
Prescription drug manufacturers have three different types of reporting obligations under the Prescription Drug Price Transparency Act (MS 62J.84):
- Price growth (subd. 3)
- New drugs (subd. 4)
- Public interest (subd. 11)
Are all of the reporting obligations currently active?
Yes. The price growth and new drug reporting types began in January 2022 and are ongoing. The public interest reporting began in January 2024 and will be ongoing as well. The timing of the price growth and new drug reporting is based on the date of drug pricing events (introduction to market or price increase), and the public interest reporting is quarterly based on a list published by MDH.
Are drug manufacturers required to register even if they don’t have any current reporting obligations?
Yes. All drug manufacturers licensed in Minnesota need to register.
How will manufacturers know what to report?
For existing reporting on new-to-market and on drugs with certain levels of price growth, manufacturers are still responsible for identifying their reporting obligations based on the statutory thresholds.
For public interest reporting, MDH will publish the list of drugs for reporting online quarterly and will notify manufacturers of the drugs requiring reporting. All lists posted by MDH are available on the Public Interest Lists page.
Where will manufacturers submit new reports?
Manufacturers will use the same portal for all three report types. Reporting templates are available for download within the online portal.
Where can manufacturers find reporting guidance for all report types?
Guidance on all three reporting streams is available online in the Form and Manner Reporting Guidance Document in the Reporting Resources section above.
Where can I find resources for reporting?
Go to the Reporting Resources section above.
Pharmacies
What drug price reporting obligations do Pharmacies have in MN?
Pharmacies have one type of reporting obligation under the Prescription Drug Price Transparency Act (MS 62J.84): Public interest (subd. 12).
How will pharmacies know what to report?
For public interest reporting, MDH will publish the list of drugs for reporting online quarterly and will notify pharmacies of the drugs requiring reporting. All lists posted by MDH are available on the Public Interest Lists page.
How can a pharmacy request an extension or exemption from reporting?
A pharmacy may request an extension or exemption within MDH’s online portal.
Are pharmacies required to register even if they don’t have any current reporting obligations?
Yes. All pharmacies licensed in Minnesota need to register.
Are pharmacies required to report even if they do not purchase or dispense any of the drugs on a given public interest list?
Yes. All pharmacies lisdensed in Minnesota are required to report unless they have requested and been approved for an extension or expemtion within the portal. Reporting entities may enter zeros for drugs they did not dispense for the reporting period. This means entering zeros in multiple data fields on the template.
If you did not dispense any of the drugs on the list, you may download the 'Download Report Zeros' template in the Portal, which is pre-populated with all relevant zeros. You must then upload that template and certify that you did not dispense those drugs for the reporting period.
Please note that future lists may include drugs that your organization does provide.
For more instruction on pharmacy reporting, view the pharmacy reporting resources on MDH's Rx Data Reporting Help page.
Where can I find resources for reporting?
Go to the Reporting Resources section above.
Pharmacy Benefit Managers
What drug price reporting obligations do Pharmacy Benefit Managers have in MN?
Pharmacy benefit managers (PBMs) have one type of reporting obligation under the Prescription Drug Price Transparency Act (MS 62J.84): Public interest (subd. 13).
How will PBMs know what to report?
For public interest reporting, MDH will publish the list of drugs for reporting online quarterly and will notify PBMs of the drugs requiring reporting. All lists posted by MDH are available on the Public Interest Lists page.
Are PBMs required to register even if they don’t have any current reporting obligations?
Yes. All PBMs licensed in Minnesota need to register.
Where can I find resources for reporting?
Go to the Reporting Resources section above.
Wholesalers
What drug price reporting obligations do Wholesalers have in MN?
Wholesalers have one type of reporting obligation under the Prescription Drug Price Transparency Act (MS 62J.84): Public interest (subd. 14).
How will wholesalers know what to report?
For public interest reporting, MDH will publish the list of drugs for reporting online quarterly and will notify wholesalers of the drugs requiring reporting. All lists posted by MDH are available on the Public Interest Lists page.
Are wholesalers required to register even if they don't have any current reporting obligations?
Yes. All wholesalers licensed in Minnesota need to register.
Where can I find resources for reporting?
Go to the Reporting Resources section above.